Novartis shares down as failed cholesterol drug study increases pipeline pressure
Pelacarsen lowered Lp(a) but did not cut deaths, heart attacks or strokes in a late-stage study, deepening pressure on Novartis’ pipeline.
- Late on Friday, Novartis announced its experimental heart drug pelacarsen failed a late-stage study, not reducing heart attacks or strokes in patients with high Lp.
- Shares of Novartis fell 3.9% on Monday morning in Zurich, marking the company's biggest decline in over four months as investors questioned its pipeline strategy.
- The disappointment increases pressure on upcoming data for del-desiran, an experimental muscular dystrophy drug Novartis acquired for $12 billion last year.
- Separately, Novo Nordisk halted its HERMES and ATHENA trials for ziltivekimab on Monday after a data monitoring committee found a "low likelihood" of success.
- These dual failures raise questions about the inflammatory-disease hypothesis that underpinned both medicines, as Amgen and Eli Lilly continue advancing competing Lp-lowering late-stage trials.
23 Articles
23 Articles
Novo Nordisk decided to close in advance two clinical studies evaluating ziltivekimab, its experimental medicine for the treatment of patients with heart failure and inflammation, after concluding that it was unlikely to reach the expected clinical outcomes. Exclusive material for subscribers. To have full access, access the material link and register.
Pelacarsen lowers an important risk factor for cardiovascular diseases. However, this alone does not seem to protect against life-threatening events.
Novartis is developing a drug with the active ingredient pelacarsen, which is intended to reduce the risk of heart attacks and strokes. After years of research, the pharmaceutical company is now breaking down the study - the share is also under pressure.
The Swiss pharmaceutical company's papers fell by 3.3 percent on Monday. The new heart medication Pelacarsen missed its target in a study. The share is under pressure.
Coverage Details
Bias Distribution
- 67% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
